Ionis Pharmaceuticals (NASDAQ:IONS) Stock Rating Reaffirmed by William Blair
William Blair reiterated their outperform rating on shares of Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) in a research note issued to investors on Monday, RTT News reports. Several other equities research analysts also recently commented on the stock. The Goldman Sachs Group boosted their target price on shares of Ionis Pharmaceuticals from $25.00 to $28.00 […]
More Stories
Small Business Administration Suspends 111,620 California Borrowers Suspected of $8.6 Billion Fraud
By Naveen Athrappully The Small Business Administration (SBA) has suspended 111,620 California borrowers suspected of committing fraudulent activity related to...
Freight Data Indicate Early US Industrial Rebound as Midwest Truck Volumes Jump
By Tom Ozimek U.S. freight markets are showing signs of a shift toward domestically driven industrial activity, with truckload volumes...
Musk Offers Legal Fees for Anyone Sued Who ‘Speaks the Truth’ About Epstein
By Rachel Roberts Tech billionaire Elon Musk said he will pay the legal fees of anyone who speaks out about...
FBI Releases New Images of Potential Suspect in Nancy Guthrie Kidnapping
By Zachary Stieber The FBI on Feb. 10 released new images and videos showing a person outside the home of...
UK PM Starmer’s Communications Director Quits Over Mandelson–Epstein Scandal
By Owen Evans British Prime Minister Keir Starmer’s communications director, Tim Allan, resigned on Feb. 9, a day after Chief...
California Refinery Closures Spell Trouble for Fuel Prices, Supply: Experts
By Rob Sabo Several energy companies have announced the closure of some of their refineries in California in recent months,...